Graves‘ disease
Conditions
Interventions
Antithyroid drug treatment group (ATD group) and radioactive iodine treatment group (RAI group):None
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: This study was a retrospective one. The patients enrolled in the cohort were newly diagnosed GD patients who visited the endocrinology Department and the Nuclear Medicine Department of our hospital from January 2020 to December 2024. The diagnostic criteria are: consistent with hyperthyroidism (TSH suppression accompanied by elevated free thyroxine [FT4] and/or free triiodothyronine [FT3]), diffuse increase in 131I uptake, elevated TRAb and/or TSI titers, and/or accompanied by Graves' ophthalmopathy (GO).
Exclusion criteria
Exclusion criteria: 1. Age =3); 5. Use drugs that affect thyroid function, such as amiodarone/lithium agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival (RFS;Remission: Thyroid function remains normal for more than 12 months after discontinuation of ATD or RAI;After drug withdrawal, persistent TSH suppression with/without FT4 elevation occurred, and transient thyroidosis such as painless thyroiditis was ruled out.;AI treatment resistance: Persistent or recurrent hyperthyroidism persists within 6 months after RAI treatment without the use of levothyroxine.; | — |
Countries
China
Contacts
Public ContactCui Xiongying
Shanghai General Hospital
Outcome results
None listed